HOXA9 and neoplasm: The aim of this retrospective study was to investigate the clinical impact of the circulating tumor DNA (ctDNA), methylated homeobox A9, in plasma from 39 patients receiving erlotinib and bevacizumab for non-resectable biliary tract cancer.